Ulrich Jaehde
Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.
Hertz D, Jörger M, Bang Y, Mathijssen R, Zhou C, Zhang L, Gandara D, Stahl M, Monk B, Jaehde U, Beumer J. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations. Eur J Cancer 2024; 202:114024.
19.03.2024Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.
19.03.2024Eur J Cancer 2024; 202:114024
Hertz Daniel L, Jörger Markus, Bang Yung-Jue, Mathijssen Ron H J, Zhou Caicun, Zhang Liling, Gandara David R, Stahl Michael, Monk Bradley J, Jaehde Ulrich, Beumer Jan H
Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients.
Bilal M, Zoller M, Fuhr U, Jaehde U, Ullah S, Liebchen U, Büsker S, Zander J, Babouee Flury B, Taubert M. Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients. Antimicrob Agents Chemother 2023; 67:e0030923.
27.06.2023Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients.
27.06.2023Antimicrob Agents Chemother 2023; 67:e0030923
Bilal Muhammad, Zoller Michael, Fuhr Uwe, Jaehde Ulrich, Ullah Sami, Liebchen Uwe, Büsker Sören, Zander Johannes, Babouee Flury Baharak, Taubert Max
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.
Omlin A, Cathomas R, von Amsberg G, Reuter C, Feyerabend S, Loidl W, Boegemann M, Lorch A, Heidenreich A, Tsaur I, Larcher-Senn J, Buck S, Mathijssen R, Jaehde U, Gillessen S, Jörger M. Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2023; 29:1887-1893.
15.05.2023Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.
15.05.2023Clin Cancer Res 2023; 29:1887-1893
Omlin Aurelius, Cathomas Richard, von Amsberg Gunhild, Reuter Christoph, Feyerabend Susan, Loidl Wolfgang, Boegemann Martin, Lorch Anja, Heidenreich Axel, Tsaur Igor, Larcher-Senn Julian, Buck Stefan A J, Mathijssen Ron H J, Jaehde Ulrich, Gillessen Silke, Jörger Markus
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
Schmulenson E, Bovet C, Theurillat R, Decosterd L, Largiadèr C, Prost J, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Jörger M, Jaehde U. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). Br J Clin Pharmacol 2022; 88:5336-5347.
23.07.2022Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
23.07.2022Br J Clin Pharmacol 2022; 88:5336-5347
Schmulenson Eduard, Bovet Cédric, Theurillat Regula, Decosterd Laurent Arthur, Largiadèr Carlo R, Prost Jean-Christophe, Csajka Chantal, Bärtschi Daniela, Guckenberger Matthias, von Moos Roger, Bastian Sara, Jörger Markus, Jaehde Ulrich
Current status and future outlooks on therapeutic drug monitoring of fluorouracil.
Schmulenson E, Zimmermann N, Mikus G, Jörger M, Jaehde U. Current status and future outlooks on therapeutic drug monitoring of fluorouracil. Expert Opin Drug Metab Toxicol 2022; 17:1407-1422.
24.01.2022Current status and future outlooks on therapeutic drug monitoring of fluorouracil.
24.01.2022Expert Opin Drug Metab Toxicol 2022; 17:1407-1422
Schmulenson Eduard, Zimmermann Nigina, Mikus Gerd, Jörger Markus, Jaehde Ulrich
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
Mc Laughlin A, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland S, Huitema A, Steeghs N, Müller L, Fuxius S, Illerhaus G, Jörger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, For The On-Target Study Consortium. Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers (Basel) 2021; 13
14.12.2021Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
14.12.2021Cancers (Basel) 2021; 13
Mc Laughlin Anna M, Schmulenson Eduard, Teplytska Olga, Zimmermann Sebastian, Opitz Patrick, Groenland Stefanie L, Huitema Alwin D R, Steeghs Neeltje, Müller Lothar, Fuxius Stefan, Illerhaus Gerald, Jörger Markus, Mayer Frank, Fuhr Uwe, Holdenrieder Stefan, Hempel Georg, Scherf-Clavel Oliver, Jaehde Ulrich, Kloft Charlotte, For The On-Target Study Consortium
Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM)
Jörger M, Miller M, Baburina I, Jog S, Cline D, Courtney J, Hilger R, Jaehde U, Kraff S, Salamone S. Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM). Ther Drug Monit 2017; 39:617-624.
01.12.2017Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM)
01.12.2017Ther Drug Monit 2017; 39:617-624
Jörger Markus, Miller M Craig, Baburina Irina, Jog Sonali, Cline Daniel J, Courtney Jodi B, Hilger Ralf A, Jaehde Ulrich, Kraff Stefanie, Salamone Salvatore J
Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia
Henrich A, Jörger M, Kraff S, Jaehde U, Huisinga W, Kloft C, Parra-Guillen Z. Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia. J Pharmacol Exp Ther 2017; 362:347-358.
09.06.2017Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia
09.06.2017J Pharmacol Exp Ther 2017; 362:347-358
Henrich Andrea, Jörger Markus, Kraff Stefanie, Jaehde Ulrich, Huisinga Wilhelm, Kloft Charlotte, Parra-Guillen Zinnia Patricia
Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel.
Kraff S, Lindauer A, Joerger M, Salamone S, Jaehde U. Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel. Ther Drug Monit 2015; 37:725-32.
01.12.2015Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel.
01.12.2015Ther Drug Monit 2015; 37:725-32
Kraff Stefanie, Lindauer Andreas, Joerger Markus, Salamone Salvatore J, Jaehde Ulrich
Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy
Kraff S, Nieuweboer A, Mathijssen R, Baty F, de Graan A, van Schaik R, Jaehde U, Jörger M. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Cancer Chemother Pharmacol 2015
12.03.2015Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy
12.03.2015Cancer Chemother Pharmacol 2015
Kraff Stefanie, Nieuweboer Annemieke J M, Mathijssen Ron H J, Baty Florent, de Graan Anne-Joy, van Schaik Ron H N, Jaehde Ulrich, Jörger Markus
Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study
Jörger M, Kraff S, Huitema A, Feiss G, Moritz B, Schellens J, Beijnen J, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet 2012; 51:607-17.
01.09.2012Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study
01.09.2012Clin Pharmacokinet 2012; 51:607-17
Jörger Markus, Kraff Stefanie, Huitema Alwin D R, Feiss Gary, Moritz Berta, Schellens Jan H M, Beijnen Jos H, Jaehde Ulrich